Blood-Bath in Nasdaq Stocks

Major PBM Looks to Stem Gilead Sciences' (GILD) Hepatitis C Profits

Gilead Sciences (Nasdaq: GILD) is on watch Tuesday as one major pharmacy benefits manager (PBM) is looking to stem some of its costs.

Bloomberg reported that Express Scripts (Nasdaq: ESRX) could move to... More

UPDATE: SunTrust Upgrades Yelp (YELP) to Buy

(Updated - April 8, 2014 7:39 AM EDT)

SunTrust Robinson Humphrey upgraded Yelp (NYSE: YELP) from Neutral to Buy with a price target of $85.00 (from $100.00).

Analyst Robert S. Peck said, "Yelp stock is down 33% in the... More

Google (GOOG) Enters Deal to License Hotel Booking Software from Room 77 - Bloomberg (PCLN) (OWW)

Priceline.com, Inc. (NASDAQ: PCLN), Expedia (Nasdaq: EXPE), Ctrip.com (Nasdaq: CTRP), and Orbitz (NYSE: OWW) are on watch Monday following headlines that Google (Nasdaq: GOOG) is licensing hotel booking software from Room 77. Bloomberg said Google would be hiring Room 77's CTO and other engineers.

Analyst Ties Tech Decline to Profit Taking (P) (GRPN) (CRM) (ANGI) (ASUR)

Barrington Research analyst Jeff Houston discussed the decline in SaaS and Internet stocks in a research note Monday. Related stocks have faced heavy selling pressure recently. In Houston's view, the main cause of the decline is profit taking.

"The recent pressure on high performing SaaS and Internet stocks as well... More

Gilead Sciences, Inc. (GILD) Receives FDA Priority Review Date for Ledipasvir + Sofosbuvir NDA as HCV Treatment

Gilead Sciences, Inc. (Nasdaq: GILD) announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the companys New Drug Application (NDA) for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400 mg for the treatment of chronic hepatitis C genotype 1 infection in adults. Gilead filed the NDA for LDV/SOF on February 10, 2014, and the... More

FBN Securities Starts FireEye, Inc (FEYE) at Outperform

FBN Securities initiated coverage on FireEye, Inc (NASDAQ: FEYE) with an Outperform rating and a price target of $65.00.

For an analyst ratings summary and ratings history on FireEye, Inc click here. For more ratings news on FireEye, Inc click here.

Shares of FireEye, Inc closed at $50.36 yesterday.

UPDATE: Oppenheimer Sees Opportunity in Tech Sell-Off; Netflix (NFLX) and Yelp (YELP) Raised to Outperform

(Updated - April 7, 2014 9:30 AM EDT)

Oppenheimer upgraded Netflix (NASDAQ: NFLX) from Perform to Outperform with a price target of $419. Yelp (NASDAQ: YELP) was also upgraded to Outperform with a price target of $78. Analyst Jason Helfstein sees... More